BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

non-small cell lung cancer and triple-negative breast cancer. The company also plans to initiate studies evaluating the therapy in combination with BioNTech’s antibody-drug conjugates.

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

Brittany Pieniazek knew she had a chance of developing breast cancer. The Dyer resident’s mother and aunt had both been ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

and triple negative breast cancer (TNBC) anticipated in late 2024 and 1H 2025, respectively, by ImmuneOnco in China U.S. clinical study of SYN-2510/IMM2510 in NSCLC initiation targeted for 2H 2025 ...

We also are finalizing plans to begin the expansion portion of our trial, with an initial focus on patients with triple-negative breast cancer who have previously been treated with at least one ...

non-small cell lung cancer and triple-negative breast cancer. BioNTech is also exploring combinations with antibody-drug ...

kidney cancer and a type of hard-to-treat breast cancer called “triple negative.” The two companies have already advanced the ...

Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...

you have cancer,” said Watson. Erica had been experiencing pain in her breast, so she decided to see a doctor to have it ...